AgingResearch.NewsJoin free

Supernus Pharmaceuticals

CompanyUnited StatesFounded 2005

RORWikidata

Supernus Pharmaceuticals develops 3 assets, the furthest approved (allopregnanolone). Mostly small molecule acting on DRD2, DRD4 and DRD3; based in the United States, founded in 2005.

3
Assets
Furthest stage
Approved
9
Trials
6
Signals

Pipeline

3

  • allopregnanolone

    Positively modulates GABA-A receptors, enhancing inhibitory neurotransmission.

    Approved, Small molecule, GABRA5, GABRA1, post partum depression (Phase 3), postpartum depression (Phase 3)

  • APOKYN

    Dopamine receptor agonist that stimulates dopamine receptors to treat motor fluctuations in Parkinson's disease

    Approved, Small molecule, DRD2, DRD4, motor symptoms (Phase 3), Parkinson's disease (Phase 3)

  • apomorphine HCl

    Activates dopamine receptors to improve motor symptoms in Parkinson's disease.

    Approved, Small molecule, DRD2, DRD4, Parkinson's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms12
  • Trials10
  • Signals7
  • Similar companies6

Intelligence